FBIOP
Fortress Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.75
+1.02%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$64.26M
MomentumView details →
1D Return
+1.02%
YTD Return
+97.42%
RSI (14)
50.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$64.26M
RSI (14)
50.6
MomentumView details →
1D Return
+1.02%
YTD Return
+97.42%
Similar companies
Latest newsMore news →
Crystalys Therapeutics announced a $130 million Series B financing to support late-stage global development and commercialization preparation for dotinurad.22d agoFortress Biotech, Inc. held its Q2 2026 earnings call on August 12, 2026.23d agoCrystalys Therapeutics closed a $130 million Series B financing to support clinical development of dotinurad for gout.39d ago